Pharmaids Pharmaceuticals Ltd. Intrinsic Value
PHARMAID · NSEon the next trading day
Valuation
Blended fair value using DCF and peer comparison methods.
Pharmaids Pharmaceuticals Ltd. Intrinsic Value Analysis
A current price is not available for Pharmaids Pharmaceuticals Ltd. (PHARMAID), so a price-to-value comparison cannot be shown. Stored data does not currently provide a positive intrinsic-value estimate for this page.
Current stored data does not provide a usable DCF or peer fair value.
How Understock Calculates Intrinsic Value
Understock follows the company's stored valuation classification. Where DCF applies, the model discounts projected or normalized cash flows and terminal value using stored assumptions. Peer valuation compares available company multiples with medians from matched industry or sector companies, with a curated peer-group fallback where database matches are unavailable; the contributing multiples and their weights depend on sector rules and available data. When neither method has a usable value, the page reports that an estimate is unavailable. DCF and peer estimates can differ because they use different assumptions, financial metrics, and market reference points.
Review this company's DCF valuation · Learn how DCF works · Use the DCF calculator · See Pharmaids Pharmaceuticals Ltd. peer valuation · What intrinsic value means
The intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.
Pharmaids Pharmaceuticals Ltd. Peer Comparison
How this company stacks up against sector peers on valuation and quality metrics.
Healthcare · 8 peers · sector medians shown
| Company | Mkt Cap | P/E | P/B | EV/EBITDA | ROE | Net Margin | Rev CAGR 3y |
|---|---|---|---|---|---|---|---|
Pharmaids Pharmaceuticals Ltd. PHARMAID · you | ₹118 Cr | -29.9× | 1.7× | — | -5.8% | — | — |
| Sector median | — | 34.0× | 2.9× | 18.6× | 8.9% | 0.1% | 11.7% |
| ONE GLOBAL SERVICE PROVIDER LIMITED ONEGLOBAL | ₹1,163 Cr | 15.7× | 63.1× | — | 401.3% | 0.1% | — |
| Laxmi Dental Limited LAXMIDENTL | ₹1,099 Cr | 39.2× | 4.7× | 26.4× | 11.9% | 10.4% | 19.8% |
| Sigachi Industries Limited SIGACHI | ₹1,041 Cr | 40.0× | 2.3× | — | 5.8% | 0.1% | — |
| Health X Platform Limited HEALTHX | ₹954 Cr | 796.5× | 1.5× | — | 0.2% | 0.1% | 8.3% |
| Bharat Parenterals Limited BPLPHARMA | ₹930 Cr | 96.0× | 2.9× | — | 3.0% | 0.1% | — |
| Wanbury Limited WANBURY | ₹915 Cr | 16.4× | 23.6× | — | 144.2% | 0.0% | — |
| Kopran Limited KOPRAN | ₹893 Cr | 34.0× | 1.6× | 13.4× | 4.8% | 3.8% | 7.3% |
| Anlon Healthcare Limited AHCL | ₹846 Cr | 23.3× | 3.3× | 18.6× | 12.6% | 16.9% | 15.1% |
Pharmaids trades at a discount to sector peers on P/E (-29.9× vs median 34.0×). This may signal undervaluation — or reflect lower expected growth or higher perceived risk versus the peer group.
Business quality
Valuation
Returns
Growth
Efficiency
Liquidity & Solvency
Financial health
Piotroski F-Score, Altman Z-Score, and key solvency ratios.
Full financial data
Charts and annual statements for income, balance sheet and cash flow.
Income trend
Revenue, profit and margin trends over time.
Cash flow
Where cash comes from and where it goes.
Balance sheet
Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.